302962-49-8

• 常用中文名：达沙替尼
• 常用英文名：Dasatinib (BMS-354825)
• CAS号：302962-49-8
• 分子式：C₂₂H₂₆ClN₇O₂S
• 分子量：488.005
• 相关类别： 原料药 抗肿瘤药 替尼类抗肿瘤药
• 发布时间：2018-06-21 10:14:27
• 更新时间：2024-01-02 18:02:58
• Dasatinib (BMS-354825)是 Bcr-Abl 和 Src 家族酪氨酸激酶抑制剂,抑制Abl, Src,c-Kit和c-KitD816V 的 IC50 分别为0.6,0.8,79和37 nM。

名称

• 中文名: 达沙替尼
• 英文名: Dasatinib
• 中文别名: N-(2-氯-6-甲基苯基)-2-[[6-[4-(2-羟乙基)哌嗪-1-基]-2-甲基嘧啶-4-基]氨基]-1,3-噻唑-5-甲酰胺; 5-噻唑甲酰胺,N-(2-氯-6-甲基苯基)-2-[[6-[4-(2-羟基乙基)-1-哌嗪基]-2-甲基-4-嘧啶基]氨基]; 达沙替尼（无水）
• 英文别名: Dasatinib; Sprycel; N-(2-Chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide; N-(2-Chlor-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazol-5-carboxamid; Dasatinib Tablets; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

物化性质

• 密度: 1.4±0.1 g/cm3
• 熔点: 275-286°C
• 分子式: C₂₂H₂₆ClN₇O₂S
• 分子量: 488.005
• 精确质量: 487.155731
• PSA: 134.75000
• LogP: 2.24
• 外观性状: 灰白-黄色固体
• 折射率: 1.688
• 储存条件: -20°C Freezer
• 计算化学:

  1.疏水参数计算参考值（XlogP）:3.6

  2.氢键供体数量:3

  3.氢键受体数量:9

  4.可旋转化学键数量:7

  5.互变异构体数量:11

  6.拓扑分子极性表面积135

  7.重原子数量:33

  8.表面电荷:0

  9.复杂度:642

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

生物活性

• 描述: Dasatinib (BMS-354825)是 Bcr-Abl 和 Src 家族酪氨酸激酶抑制剂,抑制Abl, Src,c-Kit和c-KitD816V 的 IC50 分别为0.6,0.8,79和37 nM。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> 蛋白酪氨酸激酶 >> BCR-ABL
  信号通路 >> 蛋白酪氨酸激酶 >> SRC
  研究领域 >> 癌症
• 靶点:

  IC50: 0.6 nM/0.8 nM (AblWT/Src)[1] IC50: 79 nM/37 nM (c-KitWT/c-KitD816V)[2]

• 体外研究: 达沙替尼在较窄的范围内(IC50≤1.7nM)有效抑制野生型Abl激酶和除T315I外的所有突变体。与伊马替尼相比,达沙替尼(IC50：0.8 nM)对Ba/F3细胞中表达野生型Bcr-Abl的细胞的效力高出325倍[1]。
• 体内研究: 在第10天开始每日用达沙替尼(50mg/kg)治疗。使用该方法,在治疗后6天(第16天,P = 0.014)观察到BCPAP原位肿瘤生长的显着抑制,其持续至第23天和与载体治疗的小鼠相比,29(P = 0.0003)[3]。达沙替尼(50 mg/kg)在大鼠中的代谢研究表明,达沙替尼是主要的循环成分,而多种代谢物在给药后4小时对剩余的40-60％的样品放射性有贡献[4]。
• 激酶实验: 使用野生型和突变型谷胱甘肽S-转移酶（GST）-Ab1融合蛋白（c-Abl氨基酸220-498）的激酶测定进行了微小的改变。 GST-Abl融合蛋白在使用前从谷胱甘肽 - 琼脂糖珠中释放出来; ATP的浓度为5μM。在用于激酶自身磷酸化和体外肽底物磷酸化测定之前，立即用LAR酪氨酸磷酸酶处理GST-Abl激酶结构域融合蛋白。在30℃温育1小时后，通过加入钒酸钠（1mM）使LAR磷酸酶失活。使用磷酸酪氨酸特异性抗体4G10常规地进行比较未处理的GST-Abl激酶与去磷酸化的GST-Abl激酶的免疫印迹分析以确认酪氨酸残基和c-Abl抗体CST 2862的完全（> 95％）去磷酸化以确认GST-Abl的相等加载。激酶。 IC50测定的抑制剂浓度范围是0至5,000nM（伊马替尼和AMN107）或0至32nM（达沙替尼）。对于突变体T315I，达沙替尼浓度范围扩展至1,000nM。这些相同的抑制剂浓度用于体外肽底物磷酸化测定。在针对GST-Src激酶和GST-Lyn激酶的这些相同浓度范围内测试三种抑制剂。
• 细胞实验: 将Ba / F3细胞系一式三份接种，并与升高浓度的伊马替尼，AMN107或达沙替尼一起孵育72小时。使用基于甲硫基磺酸盐的活力测定（CellTiter96 Aqueous One Solution Reagent）测量增殖。 IC50和IC90值报告为一式四份进行的三次独立实验的平均值。 IC50和IC90测定的抑制剂浓度范围为0至2,000nM（伊马替尼和AMN107）或0至32nM（达沙替尼）。对于IC 50> 2,000 nM的突变体，伊马替尼浓度范围扩展至6,400 nM。对于突变体T315I，达沙替尼浓度范围扩展至200nM。
• 动物实验: 小鼠[3]使用雄性无胸腺裸鼠（25克; 5周龄）。制备达沙替尼（50mg / kg）用于在pH 3.0的80mM柠檬酸钠缓冲液中每日口服强饲（5天/周）。对于原位鼠模型，在第10天基于生物发光活性将小鼠随机化以接受药物或媒介物。在转移性小鼠模型中，小鼠接受达沙替尼或载体，如前所述，在心内注射（预处理）之前2天开始，或在随机化（治疗后）后第11天开始。大鼠[4]达沙替尼以0.5mg / kg口服0.5％甲基纤维素给予雄性Wistar-Han（WH）大鼠。自动化大鼠血液采集装置被编程为以预定间隔收集200μL血液。在每个时间点，将accusampler编程为将20μL血液直接发现两次（两个点）到DBS卡上。将剩余的160μL液体血液收集到含EDTA钠的管中。在以11,000rpm立即离心血液5分钟后获得血浆样品。将血浆样品储存在-80℃直至分析。将DBS样品在室温下干燥至少2小时并储存在干燥器中的塑料袋中直至样品分析。
• 参考文献:

  [1]. O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5.

  [2]. Shah NP, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91.

  [3]. Chan CM, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580-91.

  [4]. Shen Z, et al. Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal. 2012 Aug-Sep;67-68:92-7.

  [5]. Weisberg E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct;26(10):2233-44.

  [6]. Kan He, et al. Protein kinase inhibitors. Patent. US20180099960A1.

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Dasatinib Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section3. Composition/information on ingredients. Ingredient name:Dasatinib CAS number:302962-49-8 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels, refrigerated. Storage: Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified Boiling point:No data No data Melting point: Flash point:No data Density:No data Molecular formula:C22H26ClN7O2S Molecular weight:488.0 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

安全

• 危害码 (欧洲): Xi
• WGK德国: 3

合成路线

上下游产品

上游产品  7
1245157-85-0 1245157-70-3 1245157-86-1 1245157-77-0
1245157-35-0 87-63-8 103-76-4
下游产品  1
863127-77-9